Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 15/20 | 0.78 |
| ▸ | CCKBR | P32239 | 1/20 | 0.75 |
| ▸ | ECE1 | P42892 | 1/20 | 0.74 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.74 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.73 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.70 |
| ▸ | GCGR | P47871 | 1/20 | 0.69 |
| ▸ | GIPR | P48546 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29429436 | 1.00 | GLP1R (0.78) | GLP1RCCKBRECE1MUS81NR3C1 | |
| SCHEMBL29498823 | 0.98 | GLP1R (0.77) | GLP1RCCKBRECE1MUS81NR3C1 | |
| SCHEMBL30721601 | 0.98 | GLP1R (0.77) | GLP1RCCKBRECE1MUS81NR3C1 | |
| SCHEMBL29634677 | 0.98 | GLP1R (0.77) | GLP1RCCKBRECE1MUS81NR3C1 | |
| SCHEMBL29942531 | 0.97 | GLP1R (0.78) | GLP1RCCKBRECE1MUS81NR3C1 | |
| SCHEMBL30658278 | 0.96 | GLP1R (0.77) | GLP1RCCKBRECE1MUS81NR3C1 | |
| SCHEMBL30874399 | 0.95 | GLP1R (0.75) | GLP1RCCKBRECE1MUS81NR3C1 | |
| SCHEMBL29669652 | 0.95 | RXFP1 (0.77) | GLP1RCCKBRECE1MUS81NR3C1 | |
| SCHEMBL29558511 | 0.94 | GLP1R (0.77) | GLP1RCCKBRECE1MUS81NR3C1 | |
| SCHEMBL31047778 | 0.94 | GLP1R (0.78) | GLP1RCCKBRECE1MUS81NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025202284-A1 | GLP-1R ANTAGONISTS FOR THE TREATMENT OF CANCER | FIORINA PAOLO (IT) | 2025-10-02 | — | — | WO | claimed |
| EP-4623928-A1 | GLP-1R ANTAGONISTS FOR THE TREATMENT OF CANCER | Fiorina, Paolo (IT) | 2025-10-01 | — | — | EP | claimed |
| CN-122036866-A | Application and method of small peptide GLP-1 (28-36) amide in preparation of medicines for preventing and treating rice blast | 湘湖实验室(农业浙江省实验室) | 2026-05-15 | — | — | CN | disclosed |
| US-12503426-B2 | Synthetic derivatives of oleoyl-lysophosphatidylinositol (oleoyl-LPI) and uses thereof | LIPOVEXA SRL (IT) | 2025-12-23 | — | — | US | disclosed |
| US-20250312420-A1 | METHODS AND COMPOSITIONS FOR TREATING HYPOGLYCEMIC DISORDERS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-10-09 | — | — | US | disclosed |
| WO-2025202284-A1 | GLP-1R ANTAGONISTS FOR THE TREATMENT OF CANCER | FIORINA PAOLO (IT) | 2025-10-02 | — | — | WO | disclosed |
| EP-4623928-A1 | GLP-1R ANTAGONISTS FOR THE TREATMENT OF CANCER | Fiorina, Paolo (IT) | 2025-10-01 | — | — | EP | disclosed |
| CN-118994411-A | High-stability long-acting GLP-1 RAs derivative | 北京化工大学 | 2024-11-22 | — | — | CN | disclosed |
| CN-111527065-B | Synthetic derivatives of oleoyl-lysophosphatidylinositol (oleoyl-LPI) and uses thereof | 科廷大学 | 2024-05-07 | — | — | CN | disclosed |
| US-20240082361-A1 | METHODS AND COMPOSITIONS FOR TREATING HYPOGLYCEMIC DISORDERS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2024-03-14 | — | — | US | disclosed |
| CN-115536638-B | Triazole compound and application thereof | 上海交通大学 | 2023-10-13 | — | — | CN | disclosed |
| CN-116063562-A | Long-acting human recombinant glucagon-like peptide-1 and application thereof | 上海延立药业有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-112023028-B | Weight-losing application of long-acting GLP-1 analogue polypeptide | 平顶山学院 | 2023-02-17 | — | — | CN | disclosed |
| EP-4049673-A1 | GLP-1 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF POST-PRANDIAL HYPOGLYCEMIA OR CONGENITAL HYPERINSULINISM | The Trustees of the University of Pennsylvania (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20220169709-A1 | GRP78 AND/OR HSP70 INHIBITORS FOR THERAPEUTIC USE | GHP SCIENTIFIC LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503426-B2 | Synthetic derivatives of oleoyl-lysophosphatidylinositol (oleoyl-LPI) and uses thereof | GPR119, GLP1R, LPAR1 | GLP1R 2/4885CCKBR 205/4885ECE1 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.